Oral Direct Factor Xa Inhibitor Rivaroxaban in Patients With Acute Symptomatic Deep-Vein Thrombosis or Pulmonary Embolism
Oral Direct Factor Xa Inhibitor Rivaroxaban in Patients With Acute Symptomatic Deep-Vein Thrombosis or Pulmonary Embolism
This is a multicenter, randomized, open-label, assessor-blind, event-driven, non-inferiority program for efficacy with a study treatment duration of 3, 6 or 12 months in patients with confirmed acute symptomatic pulmonary embolism (PE) with or without symptomatic Deep-Vein Thrombosis (DVT) (Einstein-PE).
Within the US 'Johnson & Johnson Pharmaceutical Research & Development, L.L.C.' is sponsor.
Inclusion Criteria:
Exclusion Criteria:
Bruxelles - Brussel, 1070, Belgium
Bruxelles - Brussel, 1200, Belgium
Ostrava-Poruba, 708 52, Czechia
Usti Nad Lebem, 401 13, Czechia
Karlsbad, Baden-Wurttemberg 76307, Germany
Wellington South, 6021, New Zealand
Genéve 14, Genève 14 1211, Switzerland